Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP034: Assessment of direct healthcare cost drivers of Crohn’s disease in a Dutch population-based cohort study shows a major shiftECCO '18 Vienna
Year: 2018
Authors:

R. Lalisang1*, D. Wintjens1,2, M. Romberg-Camps3, A. van Bodegraven3, L. Oostenbrug3, J. Haans1, A. Masclee1,2, D. Jonkers1,2, M. Pierik1,2

1Maastricht University Medical Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands, 2Maastricht University Medical Centre, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands, 3Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands

DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)ECCO '18 Vienna
Year: 2018
Authors:

T. De Corte1, E. Janssens1*, K. Thorrez2, A. D'Hondt1, K. Dejaegher3, F. D'Heygere4, B. van Besien2, L. Harlet1, H. Peeters5, W. Vanmoerkercke4, P. van Hootegem6, F. Baert1

1AZ Delta Roeselare Menen, Department of Gastroenterology, Roeselare, Belgium, 2Jan Yperman Hospital, Department of Gastroenterology, Ieper, Belgium, 3Sint-Jozefskliniek, Department of Gastroenterology, Izegem, Belgium, 4AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 5AZ St. Lucas, Department of Gastroenterology, Ghent, Belgium, 6AZ St. Lucas, Department of Gastroenterology, Brugge, Belgium

DOP036: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study (ICC case series)ECCO '18 Vienna
Year: 2018
Authors:

V. Biemans1,2*, A. van der Meulen - de Jong3, C. van der Woude4, N. de Boer5, G. Dijkstra6, B. Oldenburg7, C. Ponsioen8, P. Maljaars3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

1Radboudumc, Nijmegen, The Netherlands, 2Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 3Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 4Erasmus Medical Center, Rotterdam, The Netherlands, 5VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, 6University Medical Center Groningen, Groningen, The Netherlands, 7University Medical Centre Utrecht, Utrecht, The Netherlands, 8Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands

DOP037: Postoperative anti-TNF therapy is associated with a significant reduction of both endoscopic and clinical recurrence following surgery for ileocolonic Crohn’s disease: results of a prospective nationwide cohort conducted by the GETAID chirurgie groupECCO '18 Vienna
Year: 2018
Authors:

L. Maggiori1*, A. Brouquet2, P. Zerbib3, J. Lefevre4, Q. Denost5, A. Germain6, E. Cotte7, L. Beyer-Berjot8, N. Munoz-Bongrand9, V. Desfourneaux10, A. Rahili11, J.-P. Duffas12, K. Pautrat13, C. Denet14, V. Bridoux15, G. Meurette16, J.-L. Faucheron17, J. Loriau18, F. Guillon19, E. Vicaut20, Y. Panis1, S. Benoist2

1Beaujon Hospital, APHP, Colorectal Surgery, Clichy, France, 2CHU Bicetre, APHP, Department of Oncologic and Digestive Surgery, Le Kremlin-Bicetre, France, 3CHRU Lille, Department of Digestive Surgery and Transplantation, Lille, France, 4St Antoine Hospital, APHP, Digestive Surgery, Paris, France, 5CHU Bordeaux, Digestive Surgery, Bordeaux, France, 6CHRU Nancy, Digestive Surgery, Nancy, France, 7CHU Lyon-Sud, Digestive Surgery, Lyon, France, 8CHU Marseille-Nord, Digestive Surgery, Marseille, France, 9St Louis Hospital, APHP, Digestive Surgery, Paris, France, 10CHU Rennes, Digestive Surgery, Rennes, France, 11CHU Nice, Digestive Surgery, Nice, France, 12CHU Toulouse, Digestive Surgery, Toulouse, France, 13Lariboisière Hospital, APHP, Digestive Surgery, Paris, France, 14Institut Mutualiste Montsouris, Digestive Surgery, Paris, France, 15CHU Rouen, Digestive Surgery, Rouen, France, 16CHU Nantes, Digestive Surgery, Nantes, France, 17CHU Grenoble, Digestive Surgery, Grenoble, France, 18Hopital St Joseph, Digestive Surgery, Paris, France, 19CHU Montpellier, Digestive Surgery, Montpellier, France, 20Lariboisière Hospital, APHP, Departement of Clinical Research, Paris, France

DOP039: Exploring stoma rates in Crohn’s disease in the biologic era: a population-based time trend analysisECCO '18 Vienna
Year: 2018
Authors:

C. Ma*, P.G. Kotze, A. Almutairdi, D. Tanyngoh, C. Seow, K. Novak, C. Lu, R. Panaccione, G. Kaplan

University of Calgary, IBD Unit, Division of Gastroenterology and Hepatology, Calgary, Canada

DOP040: Five-year colectomy data from the observational postmarketing ulcerative colitis study, a European registry for adults with ulcerative colitis treated with originator infliximab or conventional therapyECCO '18 Vienna
Year: 2018
Authors:

J. Panés1*, J.O. Lindsay2, N. Teich3,4, S. Lindgren5, J.-F. Colombel6, F. Cornillie7, H. Ann Flynn8, S. Huyck8, P. Stryszak8, R. Yao8, G. Philip8, W. Reinisch9

1Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2The Royal London, Barts Health NHS Trust, London, UK, 3Internistische Gemeinschaftspraxis, Leipzig, Germany, 4Faculty of Medicine, Jena University, Jena, Germany, 5Lund University, Malmo, Sweden, 6Icahn School of Medicine at Mount Sinai, New York, USA, 7Merck Sharpe and Dohme, Kriens, Switzerland, 8Merck & Co., Inc., Kenilworth, USA, 9Universitätsklinik für Innere Medizin III, Vienna, Austria

DOP041: Surgery and hospitalisation in patients with inflammatory bowel disease; 10-year follow-up of a Danish population-based inception cohortECCO '18 Vienna
Year: 2018
Authors:

B. Lo1*, I. Vind1, F. Bendtsen1, M. Vester-Andersen1,2, J. Burisch1

1Copenhagen University Hospital Hvidovre, The Gastro Unit, Medical Division, Hvidovre, Denmark, 2Zealand University Hospital, Medical Department, Køge, Denmark

DOP042: Need for ileocaecal resections, but not ileo-colic re-resections, has decreased: a nationwide study of temporal trends in Crohn surgery in Sweden 1990–2014ECCO '18 Vienna
Year: 2018
Authors:

D. Kalman1*, C. Nordenvall2, A. Hallqvist Everhov3, M.C. Sachs4, J.F. Ludvigsson5, A. Ekbom6, P. Myrelid1, O. Olén7

1Division of Surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, 2Department of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Division of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, 3Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 4Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 5Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, 6Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 7Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden

DOP043: Comparative outcomes of ileal pouch revision vs. excision for pouch failure within the American College of Surgeon National Surgical Quality Improvement ProgrammeECCO '18 Vienna
Year: 2018
Authors:

S. Holubar1*, P. Neary2, S. Shawki2, A. Aiello2, C. Delaney2, S. Steele2, T. Hull2, L. Stocchi2

1Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, USA, 2Cleveland Clinic, Clinical Transformation, Cleveland, USA

DOP044: Efficacy, safety and long-term outcome of endoscopic dilation therapy for Crohn’s disease strictures of the upper gastrointestinal tract: an international multicentre cohort study including 99 patients with 129 dilation proceduresECCO '18 Vienna
Year: 2018
Authors:

D. Bettenworth1,2*, M. Mücke3, A. Singh4, R. Lopez5, M. Goetz6, T. Matsui7, J.G. Karstensen8, N.S. Ding9, T.B. Qiu9, J. Hampe10, K. Matthes10, P.V. Valli111, F. Guo12, W. Zhu13, G. Rogler11, F. Rieder14,15

1University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, 2University Hospital Münster, Department of Medicine B, Münster, Germany, 3University Hospital Frankfurt, Department of Internal Medicine 1, Frankfurt a.M., Germany, 4Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Hospital Medicine, Medicine Institute, Cleveland, USA, 5Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA, 6University Hospital Tübingen, First Department of Internal Medicine I, Tübingen, Germany, 7Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 8Copenhagen University Hospital, Gastro Unit, Division of Endoscopy, Herlev, Denmark, 9St. Vincent Hospital, Department of Gastroenterology, Melbourne, Australia, 10University Hospital Dresden, Technical University Dresden, Medical Department 1, Dresden, Germany, 11University Hospital Zurich, Departement of Gastroenterology and Hepatology, Zurich, Switzerland, 12Jinling Hospital, School of Medicine, Nanjing University, Department of General Surgery, Nanjing, China, 13Jinling Hospital, School of Medicine Nanjing University, Department of General Surgery, Nanjing, China, 14Cleveland Clinic Foundation, Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institut, Cleveland, USA, 15Cleveland Clinic, Department of Pathobiology, Lerner Research Institute, Cleveland, USA

DOP045: Combination therapy with anti-TNF and immunosuppressive therapies is the most effective medication to prevent and treat endoscopic postoperative recurrence in patients with Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Buisson1,2*, L. Cannon3, K. Umanskiy3, R.D. Hurst3, N.H. Hyman3, A. Sakuraba4, J. Pekow4, S. Dalal4, R.D. Cohen4, B. Pereira5, D.T. Rubin4

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the Host, Clermont-Ferrand, France, 3University of Chicago Medicine, Department of Surgery, Chicago, USA, 4Inflammatory Bowel Disease Center University of Chicago Medicine, Chicago, USA, 5University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France

DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trialECCO '18 Vienna
Year: 2018
Authors:

S. Berends1,2*, M. Löwenberg2, F. Baert3, R. Mathôt1, E. Clasquin2, C. Van Der Woude4, F. Hoentjen5, P. Bossuyt6, D. Franchimont7, T. Rispens8,9, A. De Vries9, S. Vermeire10, G. D'Haens2

1Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, The Netherlands, 2Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3AZ Delta Roeselare-Menen, Gastroenterology, Roeselare-Menen, Belgium, 4Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 6Imelda GI Clinical Research Center, Gastroenterology, Bonheiden, Belgium, 7Erasme Hospital, Gastroenterology, Brussels, Belgium, 8Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam, The Netherlands, 9Sanquin Diagnostic Services, Biologicals Lab, Amsterdam, The Netherlands, 10University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium

DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIXECCO '18 Vienna
Year: 2018
Authors:

E. Dreesen1*, G. D'Haens2, F. Baert3, B. Pariente4, Y. Bouhnik5, J. vander Woude6, J. Moreau7, D. Laharie8, S. Vermeire9,10, A. Gils1

1KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2Academic Medical Centre, Amsterdam, The Netherlands, 3AZ Delta, Roeselare, Belgium, 4Hospital Claude Huriez, Lille, France, 5Hospital Beaujon, Clichy, France, 6Erasmus MC, Rotterdam, The Netherlands, 7CHU, Toulouse, Belgium, 8Hospital Haut-Lévêque, Bordeaux, France, 9University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 10KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Yarur1*, A. Bruss1, C. Fox1, P. Beniwal-Patel1, A. Patel1, B. Berens1, S. Naik2, D. Stein1

1Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, USA, 2Prometheus Laboratories, San Diego, USA

DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective studyECCO '18 Vienna
Year: 2018
Authors:

D. Tarabar1*, K. El Jurdi2, O. Yvellez2, Z. Milenkovic1, S. Petrovic1, B. Subotic1, T.P. Brocic1, I. Brcerevic1, O. Latinovic3, D.T. Rubin2

1Military Medical Academy, Belgrade, Serbia, 2University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, USA, 3Clinical Center Vojvodina, Novi Sad, Serbia

DOP050: Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experienceECCO '18 Vienna
Year: 2018
Authors:

S. Pestour1*, S. Nancey2, A.L. Charlois2, B. Bonaz1, B. Flourie2, G. Boschetti2, N. Mathieu1

1Grenoble Alpes University Hospital, University Clinic of Hepato-Gastroenterology, Grenoble, France, 2Lyon Sud University Hospital, Department of Gastroenterology, Lyon, France

DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysisECCO '18 Vienna
Year: 2018
Authors:

D. Faleck1, A. Winters1, S. Chablaney1, P. Shashi2, J. Meserve3, A. Weiss4, S. Aniwan5, J.L. Koliani-Pace6, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch7, M. Luo7, M. Bohm8, S. V Sagi8, M. Fischer8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel6, B. Shen2, W.J. Sandborn3, S. Kane5, E.V. Loftus5, B.E. Sands1, J.-F. Colombel1, P.S. Dulai3*, R. Ungaro1

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Cleveland Clinic Foundation, Cleveland, USA, 3University of California - San Diego, La Jolla, USA, 4Montefiore Medical Center, New York, USA, 5Mayo Clinic, Rochester, USA, 6Dartmouth-Hitchcock Medical Center, Lebanon, USA, 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, USA, 8Indiana University, Indianapolis, USA, 9New York University (NYU), New York, USA, 10North Shore University Hospital, Manhasset, USA, 11Lenox Hill Hospital, New York, USA, 12University of Mississippi, Jackson, USA

DOP052: Vedolizumab vs. ustekinumab for Crohn’s disease: comparative effectiveness in a real-life observational cohort study (ICC case series)ECCO '18 Vienna
Year: 2018
Authors:

V. Biemans1,2*, C. van der Woude3, A. van der Meulen - de Jong4, G. Dijkstra5, N. de Boer6, B. Oldenburg7, C. Ponsioen8, A. de Vries3, D. Wintjens2, F. Hoentjen9, M. Pierik2, Dutch Initiative on Crohn and Colitis (ICC)

1Radboudumc, Nijmegen, The Netherlands, 2Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 3Erasmus Medical Center, Rotterdam, The Netherlands, 4Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 5University Medical Center Groningen, Groningen, The Netherlands, 6VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, 7University Medical Centre Utrecht, Utrecht, The Netherlands, 8Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands

DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
Year: 2018
Authors:

D. Hudesman1, S. Chang1, P. Shashi2, A. Winters3, S. Chablaney3, J. Meserve4, A. Weiss5, S. Aniwan6, D. Faleck3, J.L. Koliani-Pace7, G. Kochhar2, B. Boland4, S. Singh4, R. Hirten3, E. Shmidt3, K. Lasch8, M. Luo8, M. Bohm9, S. V Sagi9, M. Fischer9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, S. Kane6, E.V. Loftus6, B.E. Sands3, W.J. Sandborn4, J.-F. Colombel3, P.S. Dulai4*

1New York University (NYU), New York, USA, 2Cleveland Clinic Foundation, Cleveland, USA, 3Icahn School of Medicine at Mount Sinai, New York, USA, 4University of California - San Diego, La Jolla, USA, 5Montefiore Medical Center, New York, USA, 6Mayo Clinic, Rochester, USA, 7Dartmouth-Hitchcock Medical Center, Lebanon, USA, 8Takeda Pharmaceuticals U.S.A., Inc., Deerfield, USA, 9Indiana University, Indianapolis, USA, 10North Shore University Hospital, Manhasset, USA, 11Lenox Hill Hospital, New York, USA, 12University of Mississippi, Jackson, USA